Sai Life Sciences Powers Up Drug Discovery with New Integrated CMC Partnership

Image Source: www.sailife.com

Sai Life Sciences Limited announced a strategic integrated Chemistry, Manufacturing, and Controls (CMC) partnership aimed at expediting drug development for innovator companies. This collaboration offers end-to-end solutions from discovery through manufacturing, reducing timelines, risks, and complexities for pharma and biotech clients globally, leveraging Sai’s advanced capabilities and global footprint.

Sai Life Sciences, a leading Contract Research, Development, and Manufacturing Organization (CRDMO), has unveiled an integrated Chemistry, Manufacturing, and Controls (CMC) partnership tailored to accelerate drug development for innovator pharmaceutical and biotech companies. This integrated approach streamlines services, reduces cycle times, and addresses complex challenges across the drug development value chain.

Comprehensive Integrated CMC Partnership

Sai Life Sciences offers a seamless end-to-end partnership combining chemistry, process development, analytical services, and manufacturing into an integrated workflow.

Clients benefit from early involvement of process chemists, risk mitigation, and smoother tech transfer enabling faster scale-up from discovery through late-stage development.

Focus on Accelerating Innovator Programs

The partnership targets innovator pharma and biotech firms aiming to bring new chemical entities (NCEs) to clinical trials faster.
Adoption of streamlined project management, advanced automation, and high-throughput technologies bolsters speed and precision.
Close collaboration across research, development, and manufacturing functions reduces delays and decision turnaround time.

Global Footprint and Expertise

Facilities spread across Hyderabad (India), Boston (USA), and Manchester (UK) offer a global service platform.
Over two decades of experience delivering value across 300+ global pharma and biotech clients underpin Sai’s credibility.
Expertise spans synthetic chemistry, analytical development, bioanalysis, and commercial manufacturing with a focus on regulatory compliance.

Strategic Impact and Growth

The integrated CMC model supports drug developers in navigating complex modalities like peptides, ADCs, and conjugates.
Sai reported strong revenue and profit growth, reflecting heightened demand for integrated and risk-reducing partnerships.
This partnership aligns with broader industry shifts toward deeper collaboration, cost containment, and accelerated timelines.

Sources: Sai Life Sciences, Drug Discovery & Development, Capital Market, PharmaSource

Stay Ahead – Explore Now! Assam’s Budget Blues: How Lower Growth Could Impact Fiscal Health in FY26

STORIES YOU MAY LIKE

Image Source: Puthiya Vidiyal

Breaking the Silence on PCOS: Awareness, Causes and Cure Strategies

Image Source: Instagram

Lemon Tree Hotels’ Growing Gujarat Footprint Welcomes Sophisticated Stays in Gandhidham

Image Source: Business Standard

Persistent Systems Surges with $406.2M Revenue in Q2 FY26, Posting 17.6% YoY Growth and Strong Profit Margins

Image Source: The Guardian

Fueling Industry, Warding Uncertainty: South Korea’s Crude Oil Import Story in September

Image Source: INDIA MART

Capital Raised, Share Base Expanded: Asian Hotels North’s Rs 765 Crore Preferential Issue Unveiled

Image Source: Dainik Bhaskar

Silver Rush Paused: ICICI Prudential and Groww Hit the Brakes on Silver ETF Fund Investments

Image Source: Realty Plus Magazine

From NOI to LTV: Mindspace REIT Prepares Big Financial Tune-Up

Top Searches

Suggestions

Sai Life Sciences Powers Up Drug Discovery with New Integrated CMC Partnership

STORIES YOU MAY LIKE

Live Blogs

Top Stories

Sai Life Sciences Powers Up Drug Discovery with New Integrated CMC Partnership

STORIES YOU MAY LIKE

Subscribe to receive the day's headlines from WOWNEWS 24X7 straight in your inbox

Live Blogs

Top Stories